PACTR2010060002033537已完成未知
A phase II, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of GMZ2 candidate malaria vaccine in Gabonese, Bukinabe, Ghanaian, and Ugandan children aged 12 to 60 months
Statens Serum Intitute0 个研究点目标入组 1,840 人开始时间: 2010年4月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1,840
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 Month(s) 至 60 Month(s)（—）
- 性别
- All
入选标准
- •1.Children aged 12 - 60 months inclusive at the time of the first dose
- •2.Healthy by medical history and physical examination
- •3.Signed or thumb-printed Informed Consent by guardian/parent. Where guardian/parent cannot sign, a witness will be asked to sign to indicate that the procedures were understood and consent was given.
- •4.Resident in the study villages during the whole clinical trial period
排除标准
- •1.Symptoms, physical signs of disease that could interfere with the interpretation of the clinical trial results or compromise the health of the subjects if they were vaccinated
- •2.Immunosuppressive therapy (steroids, immune modulators or immune suppressors) within three (3) months prior recruitment. (for corticosteroids, this will mean prednisone, or equivalent, ¿ 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- •3.Cannot be followed for any social, psychological or geographical reasons.
- •4.Use of any investigational drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use up to the end of the child¿s participation in this clinical trial.
- •5.Suspected or known hypersensitivity to any of the vaccine components or to any vaccine.
- •6.Acute or chronic, clinically significant hepatic or renal functional abnormality.
- •7.Anaemia associated with clinical signs or symptoms of decompensation or haemoglobin < 7.0 g/dL.
- •8.Planned administration of a vaccine not foreseen by the trial protocol within 30 days of the first dose of vaccine. An exception, is the receipt of an EPI or licensed vaccine (measles, oral polio, Hib, meningococcal and combined diphtheria/ pertussis/ tetanus vaccines) which may be given 14 days or more before or after vaccination
- •9.Presence of chronic illness that, in the judgement of the investigator, would interfere with the study outcomes or pose a threat to the participant¿s health.
- •10.Administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period
- •11.History of surgical splenectomy.
- •12.Severe malnutrition at screening defined as weight for age Z-score less than 3
研究者
相似试验
进行中（未招募）
不适用
A clinical study to evaluate the efficacy to stop the bleeding and safety of TT-173 applied in the donor site of patients undergoing skin graft.EUCTR2013-002784-25-ESThrombotargets Europe
进行中（未招募）
不适用
A phase II, randomized, double-blind, controlled study to evaluate the immune responses, safety and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis who have relapsed despite anti-TNFa biological therapyMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2009-012041-35-BEeovacs SA48
进行中（未招募）
不适用
A phase II, randomized, double-blind, controlled study to evaluate the immune responses, safety and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis who have relapsed despite anti-TNFa biological therapyMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2009-012041-35-BGeovacs SA48
已完成
2 期
A phase II study of the Cuban adult formulation tetanus and diphtheria vaccine.Tetanustetanus and diphtheriaClostridium InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsCorynebacterium InfectionsActinomycetales InfectionsDiphtheriaRPCEC00000059Finlay Institute225
已完成
2 期
A phase II study of the Cuban vaccine against tetanus and diphtheria VA-DIFTET.tetanus and diphtheriaClostridium InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsCorynebacterium InfectionsActinomycetales InfectionsTetanusDiphtheriaRPCEC00000058Finlay Institute300